The liver is one of the body’s most metabolically active organs, responsible for filtering toxins, regulating fat metabolism, and maintaining energy balance. As rates of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) continue to rise globally, researchers have been investigating whether natural compounds can support liver function at the cellular level.
Urolithin A is a compound produced in the gut when certain bacteria metabolize ellagitannins: polyphenols found in foods like pomegranates, walnuts, and berries. Emerging research suggests it may influence several pathways relevant to liver health, including fat accumulation, oxidative stress, mitochondrial quality, and the gut-liver axis. Here is an honest look at what the current evidence shows, and where the gaps remain.
Key Takeaways
- Multiple animal studies suggest urolithin A may reduce fat accumulation in the liver by promoting lipophagy and suppressing abnormal lipid metabolism [1].
- Urolithin A activates the Nrf2 antioxidant pathway, which appears to protect liver cells from oxidative damage in preclinical models [2].
- Its ability to support mitochondrial quality control (mitophagy) is mechanistically relevant because mitochondrial dysfunction is a key driver of fatty liver disease [3].
- Individual differences in gut bacteria mean not everyone produces urolithin A from food equally; direct supplementation bypasses this variability [4].
- Research on urolithin A and the liver is promising but almost entirely in animal models: no large human clinical trials specifically targeting liver disease have been published yet.
How Urolithin A Reaches the Liver
Urolithin A is not consumed directly from food: it is made by specific gut bacteria from ellagitannin precursors. Not everyone produces it efficiently; people vary considerably in their gut microbial capacity to generate urolithin A from the same diet [4]. Once produced in the gut, urolithin A is absorbed, and in older adults taking it daily most of the urolithin A in blood is the conjugated form rather than the parent compound [11].
Standard oral urolithin A has limited bioavailability, partly due to how it is absorbed and processed. Researchers have experimented with delivery systems such as liposome nanoparticles coated with gum arabic to improve uptake and liver targeting. In one animal study, this nanoparticle formulation showed improved bioavailability and greater activity against fatty liver changes compared to unencapsulated urolithin A [5]. This line of research is still early-stage but points to formulation as an important variable.
Urolithin A and Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excess fat buildup in liver cells, often driven by poor diet, insulin resistance, and mitochondrial dysfunction. Several animal studies have examined whether urolithin A can reduce hepatic fat accumulation.
Research note: As summarised by FDA, the notifier states that no adverse toxicological effects were seen in a 90-day rat study at diets up to 3,451 mg/kg body weight per day in males and 3,826 mg/kg in females, the highest levels tested [13].
In a mouse model of fructose-induced fatty liver, urolithin A was found to suppress abnormal lipid metabolic reprogramming in liver cells and promote a process called lipophagy: the selective breakdown of fat droplets inside cells via autophagy pathways [1]. This suggests urolithin A may help liver cells clear excess fat more efficiently rather than letting it accumulate. Separately, a study investigating how individual differences in urolithin A production capacity affect liver outcomes found that mice capable of producing more urolithin A from ellagic acid had better outcomes on markers of non-alcoholic fatty liver disease [4], reinforcing that urolithin A itself, rather than the precursor, may be the active player.
The immunomodulatory properties of urolithin A may also contribute to its effects on metabolic liver disease. Chronic low-grade liver inflammation is a driver of progression from simple fat accumulation to more serious liver damage, and urolithin A has been studied for its capacity to modulate inflammatory signaling in metabolic contexts [6].
Mitochondrial Quality Control: A Core Mechanism
One of the most studied mechanisms of urolithin A is its ability to promote mitophagy: the selective removal and recycling of damaged mitochondria. This process is critical for liver health because the liver relies on healthy mitochondria for fat oxidation, energy production, and detoxification. When mitochondria accumulate damage, fat metabolism falters and oxidative stress rises.
Research has highlighted mitochondrial quality control as a central factor in MASLD progression. Impaired mitophagy and mitochondrial turnover are consistently observed in fatty liver disease, and restoring these processes is considered a promising therapeutic target [3]. Urolithin A is reported to stimulate mitophagy in cells and animals, which gives a plausible but unproven rationale for liver benefits. In a mouse liver study, blocking mitophagy did not remove urolithin A’s protection, while silencing Nrf2 did, and liver-specific mitophagy studies in humans are still lacking [2][10].
By promoting the clearance of dysfunctional mitochondria and the generation of healthier replacements, urolithin A may help maintain the liver’s capacity to process fats and reduce the cellular stress that drives inflammation and fibrosis over time.
Oxidative Stress Protection via the Nrf2 Pathway
The Nrf2 transcription factor is the body’s master regulator of antioxidant defenses. When activated, it switches on genes that produce protective enzymes capable of neutralizing reactive oxygen species and repairing oxidative damage. The liver, as a primary detoxification organ, is especially reliant on robust Nrf2 signaling.
In mice, blocking mitophagy did not remove urolithin A's liver protection, but silencing Nrf2 did
Protection from acetaminophen injury
In mice given an acetaminophen overdose, urolithin A protected against liver injury and beat the standard antidote NAC on dose and time window.
Protection stayed
Inhibiting mitophagy failed to prevent urolithin A's protection, in mice and in liver cells.
Protection was lost
Silencing the Nrf2 gene compromised the protection, both in mice and in cells.
No liver signal in a 28-day trial
In 50 healthy middle-aged adults, liver enzymes did not change significantly after 28 days of urolithin A or placebo. That is a safety check, not a test of liver protection.
The liver evidence is from mice, and it points to Nrf2 rather than mitophagy.
Mouse and liver-cell study of acetaminophen-induced liver injury; the human row is a separate, healthy-adult safety trial. Source: Gao et al., International Journal of Biological Sciences 2022; Denk et al., Nature Aging 2025.
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
In a mouse model of acetaminophen-induced liver injury, a well-established model of acute oxidative liver damage, urolithin A was found to protect liver cells via sustained activation of Nrf2 [2]. This effect was associated with reduced markers of liver cell death and lower enzyme levels indicating liver damage. Notably, the protection appeared linked to urolithin A’s ability to maintain Nrf2 activity over a prolonged period rather than a short burst.
Animal research examining aging hens given dietary urolithin A found improvements in hepatic antioxidant function tied to Nrf2 signaling pathway activation, alongside improvements in performance markers [7]. Poultry models differ substantially from humans, and this study measured antioxidant function and laying performance rather than liver disease, so it is weak support for liver-protective effects.
Alcohol-Related Liver Disease and the Gut-Liver Axis
Chronic alcohol consumption damages the liver partly through its effects on the gut microbiome and the gut-liver axis: the bidirectional communication pathway between gut bacteria and liver cells. Disruption of this axis allows harmful bacterial products to reach the liver and drive inflammation.
A 2024 study in mice with chronic alcohol-related liver disease found that urolithin A alleviated liver damage, and the mechanism involved a protein called MUP1 (major urinary protein 1), which acts as a mediator in gut-microbiota-liver axis signaling [8]. Urolithin A supplementation was associated with partial restoration of gut microbiota composition, reduced intestinal permeability, and lower liver inflammation scores in these animals. This study is particularly notable for identifying a specific molecular mediator, suggesting the effect is not merely general anti-inflammatory activity but involves defined signaling pathways.
These findings are animal data and should not be interpreted as evidence that urolithin A treats alcohol-related liver disease in humans. They do, however, provide mechanistic hypotheses worth exploring in future clinical research.
Aging and Liver Injury
The liver ages along with the rest of the body, accumulating cellular damage, declining mitochondrial function, and increasing susceptibility to oxidative stress. Research has begun examining whether urolithin A can counteract some age-related liver deterioration.
A 2026 study in aging mice found that urolithin A attenuated aging-induced liver injury by inhibiting the ubiquitination and degradation of a nuclear receptor called Nur77 [9]. Nur77 plays a role in regulating cell survival and metabolic function, and its excessive degradation is associated with aging-related liver damage. By preserving Nur77 levels, urolithin A appeared to reduce liver cell death and improve antioxidant capacity in older animals. This is a relatively novel finding that suggests urolithin A’s liver-protective mechanisms extend beyond mitophagy and Nrf2 activation to include preservation of specific regulatory proteins that decline with age.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day: The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10): adds resveratrol and CoQ10, a combination the published urolithin A trials did not test. - ProHealth Longevity Urolithin A
capsules, 500 mg: Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg: Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
Almost all liver-related research on urolithin A has been conducted in animal models, primarily mice. The only human liver data are safety measures: in 50 healthy middle-aged adults, liver enzymes did not change significantly after 28 days of urolithin A or placebo. No clinical trials specifically targeting human liver disease have been completed [12]. If you have fatty liver disease, liver enzyme abnormalities, or any diagnosed liver condition, consult a qualified healthcare provider before taking urolithin A supplements or making changes to your diet or treatment plan.
Frequently Asked Questions
Can urolithin A reverse fatty liver disease?
No human clinical trials have demonstrated that urolithin A reverses fatty liver disease. Animal studies show reductions in liver fat accumulation and inflammation through mechanisms like lipophagy and mitophagy [1], but these findings cannot be directly translated to humans without clinical evidence. Anyone with diagnosed fatty liver disease should work with a healthcare provider.
How does urolithin A affect the liver at a cellular level?
Several mechanisms have been proposed from animal research. It is reported to promote mitophagy (clearing damaged mitochondria), but in a mouse liver study blocking mitophagy did not remove its protection, which came from Nrf2 instead. It [2] activates Nrf2 antioxidant defenses [2], reduces lipid accumulation via lipophagy [1], and in aging animals preserves a protective nuclear receptor called Nur77 [9]. These are complementary pathways rather than a single action.
Does diet affect how much urolithin A the liver receives?
Yes, indirectly. Since urolithin A is made by gut bacteria from ellagitannins in foods like pomegranates and walnuts, how much reaches the liver depends heavily on individual gut microbiome composition. Research shows that people with higher urolithin A-producing gut bacteria capacity have meaningfully different responses to ellagitannin-rich foods compared to those with low capacity [4]. Supplementing with urolithin A directly bypasses this variability.
Is urolithin A relevant for alcohol-related liver damage?
Animal research suggests it may be. A mouse study found urolithin A reduced chronic alcohol-related liver injury by modulating gut microbiota composition and the gut-liver axis through a protein called MUP1 [8]. This is mechanistically interesting but remains preclinical. It should not be interpreted as a treatment for alcohol-related liver disease in people.
Can urolithin A protect the liver from medication-related damage?
In a mouse model of acetaminophen (paracetamol) overdose, a common cause of acute liver failure, urolithin A provided significant liver protection through sustained Nrf2 activation and reduced oxidative cell death [2]. This is an animal finding and does not mean urolithin A should be used as a protection strategy against medication overdose in humans.
Does urolithin A have any effect on the aging liver specifically?
A 2026 animal study found that urolithin A attenuated aging-related liver injury by preventing the breakdown of a regulatory protein, Nur77, which tends to decline with age [9]. This adds to a broader picture of urolithin A supporting cellular maintenance in aging tissues, though human aging-liver studies are not yet available.
References
- Zhang C et al. Ellagitannins-Derived Intestinal Microbial Metabolite Urolithin A Ameliorates Fructose-Driven Hepatosteatosis by Suppressing Hepatic Lipid Metabolic Reprogramming and Inducing Lipophagy. Journal of agricultural and food chemistry (2023). PMID 36825491
- Gao Z et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International journal of biological sciences (2022). PMID 35342347
- Shin S et al. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Journal of obesity & metabolic syndrome (2023). PMID 38049180
- Li F et al. Differential effects of ellagic acid on non-alcoholic fatty liver disease in mice: grouped by urolithin A-producing capacity. Food & function (2025). PMID 40171675
- Zhang L et al. Gum arabic-coated urolithin A liposome nanoparticles: Fabrication, characterization, bioavailability and improved alleviation on NAFLD activity in vivo. Carbohydrate polymers (2026). PMID 42097775
- Toney AM et al. Immunomodulatory Role of Urolithin A on Metabolic Diseases. Biomedicines (2021). PMID 33671880
- Wu L et al. Dietary urolithin a improves hepatic antioxidant function and laying performance in aging hens via Nrf2 signaling pathway activation. Poultry science (2026). PMID 41564535
- Zhang H et al. MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis. Gut microbes (2024). PMID 38889450
- Xiao J et al. Urolithin A Attenuates Aging-Induced Liver Injury by Inhibiting Nur77 Ubiquitination and Degradation. Journal of agricultural and food chemistry (2026). PMID 41837341
- Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature medicine (2016). PMID 27400265
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- Denk D et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature aging (2025). PMID 41174221
- U.S. Food and Drug Administration Agency Response Letter GRAS Notice No. GRN 000791. U.S. Food and Drug Administration (2018). source
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.